Panel Discussion: To What Degree Does Neuroplasticity Underpin Psychedelics Efficacy?

• What do we mean by neuroplasticity, and why has it become central to next-generation neuropsychiatric drug development?
• To what extent does neuroplasticity drive therapeutic efficacy, and can it be separated from hallucinogenic effects?
• How are researchers measuring neuroplasticity across preclinical and clinical settings?
• What biomarkers and technologies could help establish objective measures of neuroplastic change in patients?

Speakers:

Magali Haas

Chief Medical Officer

Psilera

Umed Boltaev

Research Director, Neuroscience

Helus Pharma

Matt Harlin

Senior Director, Discovery Research

Otsuka America Pharmaceutical, Inc

Scott thompson

Professor, Department of Psychiatry

University of Colorado Anschutz Medical Campus